{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:37:14Z","timestamp":1790710634889,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["17253"],"award-info":[{"award-number":["17253"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["022468"],"award-info":[{"award-number":["022468"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-61052-1","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T13:56:40Z","timestamp":1752847000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Synaptic enrichment of pSer129 alpha-synuclein correlates with dopaminergic denervation in early-stage Parkinson\u2019s disease"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-2862","authenticated-orcid":false,"given":"Irene","family":"Frigerio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1046-1698","authenticated-orcid":false,"given":"Martino L.","family":"Morella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber B.","family":"Winkelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3926-9148","authenticated-orcid":false,"given":"Danai T.","family":"Vorgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John JP","family":"Brev\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter A.","family":"Boiten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram L.","family":"van der Gaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael L.","family":"Calandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allert J.","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk W.","family":"Berendse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6151-4257","authenticated-orcid":false,"given":"Markus","family":"Britschgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-3649","authenticated-orcid":false,"given":"Laura E.","family":"Jonkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6175-5357","authenticated-orcid":false,"given":"Wilma DJ","family":"van de Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"61052_CR1","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem, B. R., Okun, M. S. & Klein, C. Parkinson\u2019s disease. Lancet 397, 2284\u20132303 (2021).","journal-title":"Lancet"},{"key":"61052_CR2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"61052_CR3","first-page":"1","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Prim. 3, 1\u201321 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"61052_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00401-008-0345-7","volume":"115","author":"DW Dickson","year":"2008","unstructured":"Dickson, D. W. et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson\u2019s disease. Acta Neuropathol.115, 437\u2013444 (2008).","journal-title":"Acta Neuropathol."},{"key":"61052_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3233\/JPD-2011-11046","volume":"1","author":"L Parkkinen","year":"2011","unstructured":"Parkkinen, L. et al. Disentangling the relationship between Lewy bodies and nigral neuronal loss in Parkinson\u2019s disease. J. Parkinson\u2019s Dis. 1, 277\u2013286 (2011).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"61052_CR6","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/mds.25975","volume":"29","author":"J Kraemmer","year":"2014","unstructured":"Kraemmer, J. et al. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov. Disord. 29, 1767\u20131773 (2014).","journal-title":"Mov. Disord."},{"key":"61052_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/ana.410260409","volume":"26","author":"D Scherman","year":"1989","unstructured":"Scherman, D. et al. Striatal dopamine deficiency in Parkinson\u2019s disease: role of aging. Ann. Neurol. 26, 551\u2013557 (1989).","journal-title":"Ann. Neurol."},{"key":"61052_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3389\/fnagi.2017.00330","volume":"9","author":"A Bellucci","year":"2017","unstructured":"Bellucci, A., Antonini, A., Pizzi, M. & Spano, P. The end is the beginning: Parkinson\u2019s disease in the light of brain imaging. Front. Aging Neurosci. 9, 330 (2017).","journal-title":"Front. Aging Neurosci."},{"key":"61052_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.neurobiolaging.2009.05.019","volume":"32","author":"R Frigerio","year":"2011","unstructured":"Frigerio, R. et al. Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies?. Neurobiol. Aging 32, 857\u2013863 (2011).","journal-title":"Neurobiol. Aging"},{"key":"61052_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"61052_CR11","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1001\/archneur.65.8.1074","volume":"65","author":"A DelleDonne","year":"2008","unstructured":"DelleDonne, A. et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch. Neurol. 65, 1074\u20131080 (2008).","journal-title":"Arch. Neurol."},{"key":"61052_CR12","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/mds.25952","volume":"29","author":"AA Dijkstra","year":"2014","unstructured":"Dijkstra, A. A. et al. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson\u2019s disease. Mov. Disord. 29, 1244\u20131251 (2014).","journal-title":"Mov. Disord."},{"key":"61052_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/ijms20010141","volume":"20","author":"F Longhena","year":"2019","unstructured":"Longhena, F., Faustini, G., Spillantini, M. G. & Bellucci, A. Living in promiscuity: the multiple partners of alpha-synuclein at the synapse in physiology and pathology. Int. J. Mol. Sci. 20, 141 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"61052_CR14","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/brain\/awq132","volume":"133","author":"P Garcia-Reitb\u00f6ck","year":"2010","unstructured":"Garcia-Reitb\u00f6ck, P. et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson\u2019s disease. Brain 133, 2032\u20132044 (2010).","journal-title":"Brain"},{"key":"61052_CR15","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1093\/brain\/awu057","volume":"137","author":"E Rockenstein","year":"2014","unstructured":"Rockenstein, E. et al. Accumulation of oligomer-prone \u03b1-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain 137, 1496\u20131513 (2014).","journal-title":"Brain"},{"key":"61052_CR16","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00401-020-02227-6","volume":"140","author":"Q Wu","year":"2020","unstructured":"Wu, Q. et al. Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo. Acta Neuropathol. 140, 831\u2013849 (2020).","journal-title":"Acta Neuropathol."},{"key":"61052_CR17","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim, S. et al. Transneuronal propagation of pathologic alpha-synuclein from the gut to the brain models Parkinson\u2019s disease. Neuron 103, 627\u2013641 e627 (2019).","journal-title":"Neuron"},{"key":"61052_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.brainres.2015.06.002","volume":"1628","author":"PJ Barrett","year":"2015","unstructured":"Barrett, P. J. & Greenamyre, J. T. Post-translational modification of \u03b1-synuclein in Parkinson\u05f3 s disease. Brain Res. 1628, 247\u2013253 (2015).","journal-title":"Brain Res."},{"key":"61052_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40478-022-01382-z","volume":"10","author":"TE Moors","year":"2022","unstructured":"Moors, T. E. et al. Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies. Acta Neuropathol. Commun. 10, 82 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"61052_CR20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00401-021-02329-9","volume":"142","author":"TE Moors","year":"2021","unstructured":"Moors, T. E. et al. The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson\u2019s disease brain as revealed by multicolor STED microscopy. Acta Neuropathol.142, 423\u2013448 (2021).","journal-title":"Acta Neuropathol."},{"key":"61052_CR21","doi-asserted-by":"publisher","first-page":"10224","DOI":"10.1074\/jbc.REV120.011743","volume":"295","author":"ZA Sorrentino","year":"2020","unstructured":"Sorrentino, Z. A. & Giasson, B. I. The emerging role of \u03b1-synuclein truncation in aggregation and disease. J. Biol. Chem. 295, 10224\u201310244 (2020).","journal-title":"J. Biol. Chem."},{"key":"61052_CR22","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.neuroscience.2008.01.030","volume":"152","author":"G Muntane","year":"2008","unstructured":"Muntane, G., Dalfo, E., Martinez, A. & Ferrer, I. Phosphorylation of tau and \u03b1-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer\u2019s disease, and in Parkinson\u2019s disease and related \u03b1-synucleinopathies. Neuroscience 152, 913\u2013923 (2008).","journal-title":"Neuroscience"},{"key":"61052_CR23","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1093\/brain\/awx275","volume":"140","author":"M Colom-Cadena","year":"2017","unstructured":"Colom-Cadena, M. et al. Synaptic phosphorylated \u03b1-synuclein in dementia with Lewy bodies. Brain 140, 3204\u20133214 (2017).","journal-title":"Brain"},{"key":"61052_CR24","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ajpath.2012.11.018","volume":"182","author":"D Games","year":"2013","unstructured":"Games, D. et al. Axonopathy in an \u03b1-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal\u2013truncated \u03b1-synuclein. Am. J. Pathol. 182, 940\u2013953 (2013).","journal-title":"Am. J. Pathol."},{"key":"61052_CR25","doi-asserted-by":"publisher","first-page":"11221","DOI":"10.1523\/JNEUROSCI.2780-08.2008","volume":"28","author":"J Moss","year":"2008","unstructured":"Moss, J. & Bolam, J. P. A dopaminergic axon lattice in the striatum and its relationship with cortical and thalamic terminals. J. Neurosci. 28, 11221\u201311230 (2008).","journal-title":"J. Neurosci."},{"key":"61052_CR26","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1126\/science.1097468","volume":"304","author":"RT Fremeau Jr.","year":"2004","unstructured":"Fremeau, R. T. Jr. et al. Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites. Science 304, 1815\u20131819 (2004).","journal-title":"Science"},{"key":"61052_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.31887\/DCNS.2016.18.1\/shaber","volume":"18","author":"SN Haber","year":"2016","unstructured":"Haber, S. N. Corticostriatal circuitry. Dialogues Clin. Neurosci. 18, 7\u201321 (2016).","journal-title":"Dialogues Clin. Neurosci."},{"key":"61052_CR28","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/nprot.2008.171","volume":"3","author":"PR Dunkley","year":"2008","unstructured":"Dunkley, P. R., Jarvie, P. E. & Robinson, P. J. A rapid percoll gradient procedure for preparation of synaptosomes. Nat. Protoc. 3, 1718\u20131728 (2008).","journal-title":"Nat. Protoc."},{"key":"61052_CR29","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"JP Anderson","year":"2006","unstructured":"Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739\u201329752 (2006).","journal-title":"J. Biol. Chem."},{"key":"61052_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/JPD-160779","volume":"6","author":"A Oueslati","year":"2016","unstructured":"Oueslati, A. Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: What have we learned in the last decade?. J. Parkinsons Dis. 6, 39\u201351 (2016).","journal-title":"J. Parkinsons Dis."},{"key":"61052_CR31","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1016\/j.neuron.2023.11.020","volume":"111","author":"LA Parra-Rivas","year":"2023","unstructured":"Parra-Rivas, L. A. et al. Serine-129 phosphorylation of alpha-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function. Neuron 111, 4006\u20134023 e4010 (2023).","journal-title":"Neuron"},{"key":"61052_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41531-023-00444-w","volume":"9","author":"N Ramalingam","year":"2023","unstructured":"Ramalingam, N. et al. Dynamic physiological alpha-synuclein S129 phosphorylation is driven by neuronal activity. NPJ Parkinsons Dis. 9, 4 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"61052_CR33","doi-asserted-by":"publisher","first-page":"ar10","DOI":"10.1091\/mbc.E23-07-0269","volume":"35","author":"JN Wallace","year":"2024","unstructured":"Wallace, J. N. et al. Excess phosphoserine-129 alpha-synuclein induces synaptic vesicle trafficking and declustering defects at a vertebrate synapse. Mol. Biol. Cell 35, ar10 (2024).","journal-title":"Mol. Biol. Cell"},{"key":"61052_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s40478-023-01623-9","volume":"11","author":"GM Lloyd","year":"2023","unstructured":"Lloyd, G. M. et al. Carboxyl truncation of alpha-synuclein occurs early and is influenced by human APOE genotype in transgenic mouse models of alpha-synuclein pathogenesis. Acta Neuropathol. Commun. 11, 119 (2023).","journal-title":"Acta Neuropathol. Commun."},{"key":"61052_CR35","doi-asserted-by":"publisher","first-page":"22670","DOI":"10.1074\/jbc.M501508200","volume":"280","author":"CW Liu","year":"2005","unstructured":"Liu, C. W. et al. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem. 280, 22670\u201322678 (2005).","journal-title":"J. Biol. Chem."},{"key":"61052_CR36","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s42003-022-03768-0","volume":"5","author":"C Zhang","year":"2022","unstructured":"Zhang, C. et al. C-terminal truncation modulates alpha-synuclein\u2019s cytotoxicity and aggregation by promoting the interactions with membrane and chaperone. Commun. Biol. 5, 798 (2022).","journal-title":"Commun. Biol."},{"key":"61052_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-016-0410-8","volume":"5","author":"B Spencer","year":"2017","unstructured":"Spencer, B. et al. Anti-alpha-synuclein immunotherapy reduces alpha-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. Acta Neuropathol. Commun. 5, 7 (2017).","journal-title":"Acta Neuropathol. Commun."},{"key":"61052_CR38","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1074\/jbc.M710012200","volume":"283","author":"L Devi","year":"2008","unstructured":"Devi, L., Raghavendran, V., Prabhu, B. M., Avadhani, N. G. & Anandatheerthavarada, H. K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 283, 9089\u20139100 (2008).","journal-title":"J. Biol. Chem."},{"key":"61052_CR39","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1523\/JNEUROSCI.4564-06.2007","volume":"27","author":"ML Kramer","year":"2007","unstructured":"Kramer, M. L. & Schulz-Schaeffer, W. J. Presynaptic \u03b1-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci. 27, 1405\u20131410 (2007).","journal-title":"J. Neurosci."},{"key":"61052_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrn.2016.178","volume":"18","author":"DJ Surmeier","year":"2017","unstructured":"Surmeier, D. J., Obeso, J. A. & Halliday, G. M. Selective neuronal vulnerability in Parkinson disease. Nat. Rev. Neurosci. 18, 101\u2013113 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"61052_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00401-012-0964-x","volume":"124","author":"GG Kovacs","year":"2012","unstructured":"Kovacs, G. G. et al. An antibody with high reactivity for disease-associated \u03b1-synuclein reveals extensive brain pathology. Acta Neuropathol. 124, 37\u201350 (2012).","journal-title":"Acta Neuropathol."},{"key":"61052_CR42","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s40478-022-01468-8","volume":"10","author":"MF Altay","year":"2022","unstructured":"Altay, M. F., Liu, A. K. L., Holton, J. L., Parkkinen, L. & Lashuel, H. A. Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders. Acta Neuropathol. Commun. 10, 163 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"61052_CR43","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/cne.23901","volume":"524","author":"K Taguchi","year":"2016","unstructured":"Taguchi, K., Watanabe, Y., Tsujimura, A. & Tanaka, M. Brain region-dependent differential expression of alpha-synuclein. J. Comp. Neurol. 524, 1236\u20131258 (2016).","journal-title":"J. Comp. Neurol."},{"key":"61052_CR44","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/mds.27806","volume":"34","author":"B Mollenhauer","year":"2019","unstructured":"Mollenhauer, B. et al. Longitudinal analyses of cerebrospinal fluid alpha-synuclein in prodromal and early Parkinson\u2019s disease. Mov. Disord. 34, 1354\u20131364 (2019).","journal-title":"Mov. Disord."},{"key":"61052_CR45","doi-asserted-by":"publisher","DOI":"10.1177\/1177271920950319","volume":"15","author":"E Camporesi","year":"2020","unstructured":"Camporesi, E. et al. Fluid biomarkers for synaptic dysfunction and loss. Biomark. Insights 15, 1177271920950319 (2020).","journal-title":"Biomark. Insights"},{"key":"61052_CR46","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00401-011-0815-1","volume":"121","author":"J Zhou","year":"2011","unstructured":"Zhou, J. et al. Changes in the solubility and phosphorylation of alpha-synuclein over the course of Parkinson\u2019s disease. Acta Neuropathol. 121, 695\u2013704 (2011).","journal-title":"Acta Neuropathol."},{"key":"61052_CR47","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/mds.27110","volume":"32","author":"P Eusebi","year":"2017","unstructured":"Eusebi, P. et al. Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov. Disord. 32, 1389\u20131400 (2017).","journal-title":"Mov. Disord."},{"key":"61052_CR48","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.neulet.2008.11.015","volume":"450","author":"A Ohrfelt","year":"2009","unstructured":"Ohrfelt, A. et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders\u2014A marker of synapse loss?. Neurosci. Lett. 450, 332\u2013335 (2009).","journal-title":"Neurosci. Lett."},{"key":"61052_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104708","volume":"134","author":"LE Stoyka","year":"2020","unstructured":"Stoyka, L. E. et al. Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded alpha-synuclein inclusions. Neurobiol. Dis. 134, 104708 (2020).","journal-title":"Neurobiol. Dis."},{"key":"61052_CR50","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1212\/WNL.67.7_suppl_2.S8","volume":"67","author":"L Zecca","year":"2006","unstructured":"Zecca, L., Zucca, F. A., Albertini, A., Rizzio, E. & Fariello, R. G. A proposed dual role of neuromelanin in the pathogenesis of Parkinson\u2019s disease. Neurology 67, S8\u2013S11 (2006).","journal-title":"Neurology"},{"key":"61052_CR51","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.neurobiolaging.2006.02.010","volume":"28","author":"A Kashani","year":"2007","unstructured":"Kashani, A., Betancur, C., Giros, B., Hirsch, E. & El Mestikawy, S. Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease. Neurobiol. Aging 28, 568\u2013578 (2007).","journal-title":"Neurobiol. Aging"},{"key":"61052_CR52","unstructured":"A. Abey in AD\/PD\u2122 2024 Alzheimer\u2019s & Parkinson\u2019s Diseases Conference."},{"key":"61052_CR53","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/brain\/awab242","volume":"144","author":"A Tozzi","year":"2021","unstructured":"Tozzi, A. et al. Dopamine-dependent early synaptic and motor dysfunctions induced by alpha-synuclein in the nigrostriatal circuit. Brain 144, 3477\u20133491 (2021).","journal-title":"Brain"},{"key":"61052_CR54","doi-asserted-by":"publisher","unstructured":"Chen, L. et al. Synaptic location is a determinant of the detrimental effects of alpha-synuclein pathology to glutamatergic transmission in the basolateral amygdala. Elife. https:\/\/doi.org\/10.7554\/eLife.78055 (2022).","DOI":"10.7554\/eLife.78055"},{"key":"61052_CR55","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/brain\/awz065","volume":"142","author":"V Durante","year":"2019","unstructured":"Durante, V. et al. Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. Brain 142, 1365\u20131385 (2019).","journal-title":"Brain"},{"key":"61052_CR56","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1212\/WNL.0000000000002102","volume":"85","author":"D Iacono","year":"2015","unstructured":"Iacono, D. et al. Parkinson disease and incidental Lewy body disease: Just a question of time?. Neurology 85, 1670\u20131679 (2015).","journal-title":"Neurology"},{"key":"61052_CR57","doi-asserted-by":"publisher","first-page":"27S","DOI":"10.2967\/jnumed.121.263197","volume":"63","author":"ED Wallert","year":"2022","unstructured":"Wallert, E. D. et al. Imaging dopaminergic neurotransmission in neurodegenerative disorders. J. Nucl. Med. 63, 27S\u201332S (2022).","journal-title":"J. Nucl. Med."},{"key":"61052_CR58","doi-asserted-by":"publisher","first-page":"101698","DOI":"10.1016\/j.nicl.2019.101698","volume":"22","author":"LE Jonkman","year":"2019","unstructured":"Jonkman, L. E. et al. Normal Aging Brain Collection Amsterdam (NABCA): a comprehensive collection of postmortem high-field imaging, neuropathological and morphometric datasets of non-neurological controls. NeuroImage Clin. 22, 101698 (2019).","journal-title":"NeuroImage Clin."},{"key":"61052_CR59","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.neuroscience.2014.10.008","volume":"282","author":"SN Haber","year":"2014","unstructured":"Haber, S. N. The place of dopamine in the cortico-basal ganglia circuit. Neuroscience 282, 248\u2013257 (2014).","journal-title":"Neuroscience"},{"key":"61052_CR60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0165-6147(93)90029-J","volume":"14","author":"B Giros","year":"1993","unstructured":"Giros, B. & Caron, M. G. Molecular characterization of the dopamine transporter. Trends Pharm. Sci. 14, 43\u201349 (1993).","journal-title":"Trends Pharm. Sci."},{"key":"61052_CR61","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41531-023-00604-y","volume":"9","author":"MF Altay","year":"2023","unstructured":"Altay, M. F. et al. Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases. NPJ Parkinsons Dis. 9, 161 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"61052_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"61052_CR63","doi-asserted-by":"crossref","unstructured":"Lin, C. P. et al. Nigral pathology contributes to microstructural integrity of striatal and frontal tracts in Parkinson\u2019s disease. Mov. Disord. 38, 1655\u20131667 (2022).","DOI":"10.1002\/mds.29510"},{"key":"61052_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-022-00328-8","volume":"12","author":"I Frigerio","year":"2023","unstructured":"Frigerio, I. et al. Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson\u2019s disease dementia. Transl. Neurodegeneration 12, 3 (2023).","journal-title":"Transl. Neurodegeneration"},{"key":"61052_CR65","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40478-023-01711-w","volume":"12","author":"I Frigerio","year":"2024","unstructured":"Frigerio, I. et al. Regional differences in synaptic degeneration are linked to alpha-synuclein burden and axonal damage in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol. Commun. 12, 4 (2024).","journal-title":"Acta Neuropathol. Commun."},{"key":"61052_CR66","doi-asserted-by":"publisher","first-page":"109333","DOI":"10.1016\/j.celrep.2021.109333","volume":"36","author":"L Fonseca-Ornelas","year":"2021","unstructured":"Fonseca-Ornelas, L. et al. Altered conformation of \u03b1-synuclein drives dysfunction of synaptic vesicles in a synaptosomal model of Parkinson\u2019s disease. Cell Rep. 36, 109333 (2021).","journal-title":"Cell Rep."},{"key":"61052_CR67","unstructured":"Scientific Volume Imaging. Huygens Professional. https:\/\/svi.nl\/Huygens-Professional"},{"key":"61052_CR68","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"61052_CR69","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1089\/adt.2009.9996","volume":"7","author":"M Bielefeld-Sevigny","year":"2009","unstructured":"Bielefeld-Sevigny, M. AlphaLISA immunoassay platform\u2014the \u201cno-wash\u201d high-throughput alternative to ELISA. Assay. Drug Dev. Technol. 7, 90\u201392 (2009).","journal-title":"Assay. Drug Dev. Technol."},{"key":"61052_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine, T. J. et al. National Institute on Aging\u2013Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 123, 1\u201311 (2012).","journal-title":"Acta Neuropathol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61052-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61052-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61052-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:40:30Z","timestamp":1757259630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61052-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["61052"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-61052-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors I.F., M.L.M., A.B.W., D.T.V., J.J.P.B, W.A.B., B.L.G., I.L.C., A.J.J., H.W.B., L.E.J., and W.D.J.B. declare that they have no competing interests. D.M. and M.B. are full-time employees of Roche\/F. Hoffmann-La Roche Ltd, and they may additionally hold Roche stock\/stock options.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6630"}}